Two years ago, Glenmark Pharmaceuticals had attempted to sell a minority stake in its API business to private equity funds but those plans did not fructify. Post the Q3FY21 results, the management indicated that API growth outlook remained strong for the next two-three years owing to a favourable demand-supply scenario.Glenmark Pharma’s API arm files papers with Sebi to unlock value via IPO
Two years ago, Glenmark Pharmaceuticals had attempted to sell a minority stake in its API business to private equity funds but those plans did not fructify. Post the Q3FY21 results, the management indicated that API growth outlook remained strong for the next two-three years owing to a favourable demand-supply scenario.
Subscribe to:
Post Comments (Atom)
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
Thirteen tier 2 and 3 cities register higher traffic in December than pre-COVID-19 levels.
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment